Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Leukemia|July 25, 2021
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphomaAlessandra Rossi, Stefania Orecchioni, Paolo Falvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphomaCorrado Tarella, Roberto Passera, Michele Magni, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
Blood|December 16, 2014
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutationsMargherita Bodini, Chiara Ronchini, Luciano Giacò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 TrialAndrea Gallamini, Andrea Rossi, Caterina Patti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Haematologica|August 21, 2020
A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphomaEnrico Derenzini, Saveria Mazzara, Federica Melle, et al.
Pageof 10